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Injecting-related health harms and overuse
of acidifiers among people who inject
heroin and crack cocaine in London:
a mixed-methods study
Magdalena Harris1* , Jenny Scott2, Talen Wright1, Rachel Brathwaite3, Daniel Ciccarone4 and Vivian Hope5
Abstract
Background: Venous access is a priority for people who inject drugs (PWID). Damage and scarring of peripheral
veins can exacerbate health harms, such as skin and soft tissue infections (SSTI), and promote transitions to femoral
and subcutaneous injecting. Brown heroin available in Europe requires acidification for injection preparation. In this
paper, we present mixed-methods data to explore our hypothesis of a link between overly acidic injection
solutions, venous damage and SSTI risk.
Methods: We present a structured survey (n = 455) and in-depth qualitative interview (n = 31) data generated with
PWID in London for the Care & Prevent study. Participants provided life history data and detail on injecting
environments and drug preparation practices, including the use of acidifiers. Bivariate and multivariate analyses
were conducted using a logistic regression for binary outcomes to explore associations between outcomes and
excessive acidifier use. Grounded theory principles informed inductive qualitative analysis. Mixed-methods
triangulation was iterative with results comparison informing the direction and questions asked of further analyses.
Results: Of the 455 participants, most (92%) injected heroin and/or crack cocaine, with 84% using citric as their
primary acid for drug preparation. Overuse of acidifier was common: of the 418 who provided an estimate, 36%
(n = 150) used more than ½ a sachet, with 30% (n = 127) using a whole sachet or more. We found associations
between acidifier overuse, femoral injecting and DVT, but not SSTI. Qualitative accounts highlight the role of poor
heroin quality, crack cocaine use, information and manufacturing constraints in acidifier overuse. Painful injections
and damage to peripheral veins were common and often attributed to the use of citric acid.
Conclusions: To reduce injecting-related injury and associated consequences, it is crucial to understand the
interplay of environmental and practice-based risks underpinning venous damage among PWID. Overuse of acidifier
is a modifiable risk factor. In the absence of structural supports such as safe injecting facilities or the prescribing of
pharmaceutical diamorphine, there is an urgent need to revisit injecting paraphernalia design and distribution in
order to alleviate health harms and distress among the most marginalised.
Keywords: Citric acid, Ascorbic acid, Vitamin C, People who inject drugs, Skin and soft tissue infections, Heroin, Vein
damage, Harm reduction
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Background
‘Care & Prevent’ is a five-phase mixed-methods study [1]
that explores skin and soft tissue infection (SSTI) risk,
sequelae, care and prevention with people who inject
drugs (PWID) in London. In this paper, the first in a
series on Care & Prevent findings, we explore associa-
tions between acidifier use and SSTI risk, unpack de-
tailed accounts of injection preparation practice and
discuss options for reducing acidifier related harm, using
survey and qualitative data from phases 2 and 4, respect-
ively. We focus on acidifier use because we hypothesise
a link between overly acidic injection solutions, venous
damage and SSTI risk.
Acid is necessary to prepare brown heroin (used in
Europe) and crack cocaine for injection, as these base
form drugs are poorly soluble in water. The addition of
acid promotes conversion of heroin and/or crack into a
soluble, injectable form [2]. The exact amount of acid
needed to dissolve the psychoactive opiates in heroin
varies depending on drug quality and weight as well as
type of acidifier used. Laboratory experiments using her-
oin sourced through United Kingdom (UK) street mar-
kets illustrate that 27 mg of citric acid (‘two pinches’) or
67 mg of vitamin C (ascorbic acid) is sufficient to dis-
solve the 140 mg of diamorphine base present in a 250-
mg heroin sample (selected as in upper weight range of
£10 heroin samples) [2]. Both amounts, however, are
smaller than the 100-mg citric acid and 300-mg vitamin
C sachets1 provided for injection preparation in the UK.
Promoted as ‘single use’, the 100-mg sachet weight is
dictated by manufacturing process constraints, not be-
cause it is the amount required to prepare a typical sin-
gle heroin injection [2, 3]. With the proviso that
injections also including crack cocaine require additional
acidifier, we posit that the use of more than half a sachet
of citric acid or vitamin C is extraneous to the dissol-
ution requirements of a typical £10 bag of street heroin
for injection and is potentially causative of harm.
Prior to 2003, the provision of citric acid and vitamin
C for injection preparation was in contravention of the
UK law. PWID typically used household acids, such as
lemon juice and vinegar, and purchased tubs of citric
acid and vitamin C through pharmacies and home brew
suppliers, where available. In 2000, retail access to citric
acid and vitamin C declined markedly after the Pharma-
ceutical Journal published a letter from a pharmacist
raising concerns about the legality of acidifier supply [4].
Agreements to protect against prosecution were sought
and formalised in some localities [2, 3], with PWID in-
creasingly using lemon and vinegar in others. The use of
lemon juice in injection preparation can cause the fungal
eye infection Candida endophthalmitis, with outbreaks
documented among PWID in the 1980s and 1990s [5].
New reports of eyesight problems and blindness among
PWID prompted the development and launch of single-
use citric acid sachets in 2001 and vitamin C sachets in
2003 [6]. Amendments to section 9A of the Misuse of
Drugs Act legalised their supply through medical and
harm reduction providers in 2003 (citric) and 2005 (vita-
min C).
Early evaluations of citric acid supply for injection in
the UK showed that the availability of citric acid sa-
chets attracted PWID into needle and syringe programs
(NSPs) [3] and increased attendance frequency [7], in-
dicating acceptability and widespread uptake. However,
since this early interest—largely precipitated by the law
change—there has been little research exploring the
role of acidifier in injection preparation or its potential
role in exacerbating venous damage and SSTI risk.
Legalised provision of acidifier for injection in the UK
only arose after concerted lobbying by harm reduction
organisations and providers concerned about the health
harms of household acid use. As a hard-won and neces-
sary intervention, the potential of citric acid and vita-
min C to produce, as well as avert, injecting-related
harm was understandably overlooked.
A limited literature indicates associations between vein
damage and acidifier use during injection preparation.
Ciccarone and Harris [8] tested their hypothesis of a
causal link between heroin solution acidity and venous
sclerosis in an exploratory study with PWID in London
and Philadelphia. They took still and video photographs
of the heroin preparation process, asking each partici-
pant to provide a small sample to be tested for pH be-
fore being interviewed about their injecting practice. UK
heroin solutions prepared with citric acid had a high
acidity (average pH = 2.6), close to the acidity of wine
vinegar, and almost ten times more acidic than solutions
prepared with vitamin C (avg. pH = 3.4). Pharmaceutical
heroin was the least acidic (pH =4.8); similar to injec-
tions prepared in Philadelphia (avg. pH = 4.7) where
Columbian-sourced powder heroin (hydrochloride salt
form) predominates. Salt form heroin, unlike the
Afghanistan-sourced base heroin used in the UK, is
highly soluble and does not require acidifier for injection
preparation. London participants related painful injec-
tions and vein damage to citric acid use, with Philadel-
phia participants reporting minimal vein damage or
injecting-related injury from heroin injecting. Three UK
studies report PWID participants commonly using a
whole sachet of citric acid for each heroin injection [3, 9,
10]. Qualitative studies illustrate uncertainty among
PWID about how much acid it is appropriate to use for
injection preparation and attributions of vein damage to
citric acid use [8, 11].
1Sachet: a small sealed packet with an airtight seal and waterproof
membrane. See: http://bit.ly/citricinfo
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Understanding the causes of venous sclerosis is fundamen-
tal to harm reduction initiatives for PWID. Damage and
sclerosis of peripheral veins can lead to multiple injection at-
tempts, increased blood in the environment and transitions
to femoral and subcutaneous injecting [8, 12, 13]. Femoral
vein injecting increases risk of venous insufficiency and deep
vein thrombosis (DVT) [14, 15], which can lead to venous ul-
cers, tissue necrosis, amputation and potentially fatal pul-
monary embolism. Subcutaneous injecting is associated with
SSTI such as abscesses and cellulitis. SSTI are an increasing
cause of acute and chronic morbidity among PWID [16–18].
Cross-sectional prevalence in the UK and US ranges from 10
to 36%, with lifetime prevalence as high as 70% [19–22]. Na-
tional UK data from 2014 evidence 10% of PWID reporting
hospital admission for SSTI in the preceding year [17, 23]
with hospitalisations rising annually since 2012 [18]. Dam-
aged veins not only precipitate health harms, such as hepa-
titis C, venous ulcers and SSTI, but are an acute source of
suffering for PWID [13]. Interventions attending to immedi-
ate priorities of PWID, such as maintaining venous access,
are crucial and likely to have more currency than those fo-
cused on long-term risks [13].
Methods
In this paper, we present structured survey and in-depth
qualitative interview data generated with PWID in
London for the ongoing Care & Prevent study. Study
methodology details are published [1]. Participants were
eligible if aged 18 years and older and had a history of
injecting psychoactive drugs. Recruitment took place
through drug treatment services, homeless hostels and
day centres across London. Interested participants learnt
about the study through either service staff, recruitment
flyers or an affiliated outreach team. Participants re-
ceived a £10 voucher for answering survey questions and
providing a urine sample to be tested for albuminuria
(see [1] for details), and £20 for an interview. Four hun-
dred and fifty-five PWID took part in the survey and 31
in qualitative interviews. Questionnaire and interview
data were generated concurrently between October 2017
and March 2019. Analysis followed steps outlined for
convergent design projects whereby each dataset is ini-
tially analysed separately using the appropriate qualita-
tive and quantitative analytic methods, with results
compared to inform the direction and questions asked
of further analyses and data generation [24]. Final tri-
angulation of mixed-methods data prioritised comple-
mentarity (findings greater than the sum of their parts),
while also attentive to convergence and dissonance [25].
The questionnaire was prepared using the Open Data
Kit (ODK) software and administered using the ODK
Collect application on Android tablets [26] by trained
researchers. Participants answered questions pertaining
to their: socio-demographics; drug use history; injection
preparation and administration practices (lifetime and
previous 12months); reuse and cleaning of injecting
equipment (lifetime); experience of SSTIs and other
health conditions; care-seeking and hospitalisation (life-
time). Using Stata version 15.1, the characteristics of
study population and the prevalence risk factors were
described using numbers and percentages for categorical
variables, means (standard deviations) for normally dis-
tributed continuous variables and median (95% CI) for
non-normally distributed continuous variables. Bivariate
and multivariate analyses were conducted using a logis-
tic regression for binary outcomes to explore association
between outcomes and excessive acidifier use. A priori,
we proposed the following outcomes could be associated
with using excessive acid use: injection sites related to
vein loss, e.g. groin injecting and non-antecubital fossa
(inner elbow) injecting, attempts at vein injecting, SSTIs
and sequelae of SSTIs, e.g. microalbuminuria. Where
possible associations were found in the bivariate analyses
(p < 0.10), these were further explored in multivariable
analyses to adjust for the following possible confounders:
age, gender, and injecting frequency per week.
Questionnaire participants were purposively sampled
for invitation to the qualitative interview, with attention
to capturing diversity in age, gender, injecting history
and experience of SSTI. Interviews were of 60–120 min
in duration, audio-recorded with consent and conducted
in a private room at a recruiting service, a café or the
participant’s home. Participants were invited to talk
about their life history and their drug use trajectory. De-
tail was sought about injecting environments and drug
preparation practices, including the use of acidifiers.
Field-notes were generated after each interview, noting
participant-interviewer dynamics, environmental context
and interview content to follow-up on or consider in
analysis. Interview audio-recordings were transcribed
verbatim, cleaned to ascertain anonymity and entered
into NVivo 12 for data management and analysis.
Qualitative analysis was informed by constructivist
grounded theory methods [27] with data analysed as
generated in order to inform the direction of subse-
quent interviews, coding, case selection, memo and
theory generation. Initially, M. H open coded five
transcripts line-by-line using process or gerund codes
[27]. In consultation with team members, inductive
open-codes were consolidated into focused codes.
These formed the basis of a coding frame, comprising
13 ‘first-level’ codes or categories. The coding frame
was entered into NVivo, and two researchers coded
the same four interviews against the 13 categories be-
fore coding independently. The second-stage coding
comprised inductive open coding of the data in each
category to inform analytic interpretation and theme
development. For example, the first-level category
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‘Describing and accounting for acidifier use’ com-
prised 46 pages of data. Reanalysis demarcated the fol-
lowing second level codes: ‘accounting for overuse’,
‘attributing pain and damage’, ‘obtaining acidifiers
and/or expressing preference’ and ‘taking care’. Con-
sideration and comparison of the second-level code
data then informed questions asked of quantitative
analysis, with finding triangulation from each method
generating the themes and analyses presented in this
paper. In this way, analysis has been a detailed, itera-
tive process, conducted in collaboration and with at-
tention to consistency as well as movement toward
theory generation and transferability.
Ethical approval
Ethical approval for this study was granted by the
London School of Hygiene and Tropical Medicine Ob-
servational Research Ethics Committee [12021], the
London Bridge Research Ethics Committee and Health
Research Authority [17/LO/0872]. All participants pro-
vided written consent after receiving study information
and assurance of confidentiality.
Results
Participant demographics and injection practices
In total, 455 PWID completed the questionnaire across
all study locations (see Tables 1 and 2 for participant
characteristics). Participants were predominately male
(75%, n = 341), of White ethnicity (74%, n = 336), and
reflected the ageing population of PWID in the UK, with
a mean age of 46 years. The majority were unstably
housed with 32% (n = 146) currently (past 12 months)
living in hostels, 13% (n = 61) street homeless and 3%
(n = 15) in prison or staying with friends/family (6%,
n = 28). Lifetime history of street homelessness was high,
at 78% (n = 355). Participants were asked about lifetime
experience of abscesses, cellulitis, venous ulcers and ven-
ous disease. The majority (65% n = 296) had experienced
at least one of these conditions, of whom 46% (n = 137)
reported hospitalisation. Two-thirds (62%, n = 284) re-
ported injecting in the past 12 months, with a heroin
and crack combination favoured by most (58%, n = 164).
On average, participants had commenced injecting when
25 years old, 42% (n = 192) reported injecting their pri-
mary drug for 15 or more years. The majority (79%, n =
360) were currently on opiate substitution therapy, for a
median duration of 10 years. Citric acid was the most
commonly used acidifier during drug preparation (84%,
n = 237). Participants were asked how much acidifier
they would typically use to prepare a £10 bag of heroin,
of the 418 who provided an estimate, excessive acid use
was common with 36% (n = 150) reporting using more
than ½ a sachet, of these 85% (n = 127) used a whole sa-
chet or more.
Qualitative interview participants (n = 31) reflected the
demographics of the larger sample. Most were men (71%,
n = 22), of White ethnicity (81%, n = 25), and with a mean
age of 43 years. The mean age at first injection was 23
years, with half (51%, n = 16) injecting their primary drug
for 15 or more years. Of the 30 participants asked about
acidifier use, most used citric acid (77% n = 23), with a
similar proportion as the larger sample using more than
half a sachet of acidifier (37%, n = 11). Of these, most re-
ported using a whole sachet or more (82% n = 9).
Injecting practices and health outcomes associated with
acidifier over-use
Bivariate analyses found that those who reported ex-
cessive acidifier use (more than half a sachet of acidi-
fier) had increased odds of injecting in their groin (OR
1.92 p = 0.002), being diagnosed with DVT (OR 1.82,
p = 0.010), experiencing septicaemia (OR 1.59, p =
0.0.068), testing positive for micro/macroalbuminuria
(indicative of prolonged SSTI or other source of in-
flammation) (OR 1.85, p = 0.041) and being diagnosed
with endocarditis (OR 2.04 0 = 0.113), than those who
used less (see Table 3). No association was found be-
tween acidifier overuse and SSTI history [OR 1.03,
p = 0.912], ever injecting in any other body parts, legs
(OR 1.15, p = 0.491), feet (OR 1.08, p = 0.699), hands
(OR 0.87 (p = 0.484), and arms (OR 0.69, p = 0.591),
and accessing a vein on the first attempt versus mul-
tiple attempts (OR 0.87, p = 0.484). After adjusting for
possible confounders in step-wise multivariable ana-
lyses, excessive acidifier use was associated with in-
creased odds of injecting in the groin [AOR 1.95 (95%
CI 1.29, 2.95)], diagnosis of DVT [AOR 1.87 (95% CI
1.18, 2.97)], and micro/macroalbuminuria [AOR 1.85
(95% CI 1.02, 3.35)]. Diagnoses of blood poisoning and
endocarditis did not reach traditional significance (p <
0.05) after adjustment.
Qualitative findings: accounting for (over)use of acidifier
We hypothesise that excessive acidifier use plays a causal
role in venous irritation, damage and associated complica-
tions. It is therefore of interest to explore how modifiable
this practice is. This requires an understanding of the role
acidifier (over)use plays for participants, and the social rela-
tions and contexts in which injection preparation sits. The
following section explores excessive acidifier use (as either
participant or researcher-identified) through participant ac-
counts of injecting preparation expertise, constraint and
convention, and pain and practice modification. While not
mutually exclusive, these themes indicate three distinct and
situated rationalities of acidifier use with implications for
intervention development and implementation.
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Table 1 Injecting and treatment history: PWID London 2017–2019
Demographics and injecting history N = 455
Demographics N (%)
Age (years), mean (SD) 45.7 (9.0)
Gender
Male 341 (75.0)
Female 114 (25.0)
Ethnicity
White or White British 336 (73.9)
African, Caribbean or Black British 50 (11.0)
Asian or Asian British 12 (2.6)
Mixed ethnicity 27 (5.9)
Other 30 (6.6)
Place of residence, past 12 months
Own house/flat 169 (37.1)
Shared house/flat 25 (5.5)
At parents, relatives or friends house 28 (6.2)
Hostel 146 (32.1)
Street homeless 61 (13.4)
Gaol/prison 15 (3.3)
Other 11 (2.4)
Ever homeless
No 100 (22.0)
Yes 355 (78.0)
Injecting history
Age of injecting initiation, mean (SD) 24.8 (8.7)
Duration injecting main drug
One year or less 57 (12.5)
2–4 years 70 (15.4)
5–7 years 50 (11.0)
8–10 years 55 (12.1)
11–14 years 31 (6.8)
15+ years 192 (42.2)
Injected in the last 12 months
Yes 284 (62.4)
No 171 (37.6)
Main drug injected in last 12 months N = 284
Heroin and crack combined 164 (57.8)
Heroin only 97 (34.2)
Stimulants (amphetamine, methamphetamines, speed) 11 (3.9)
Crack only 5 (1.8)
Methadone 4 (1.4)
Cocaine 2 (0.7)
Methedrone 1 (0.4)
Main drug injected in the past, if had not injected in last 12 months n = 171
Heroin only 102 (59.7)
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Expertise: crack and cutting agents
Some participants adopted an educative role in the inter-
view encounter, drawing on personal experience to evi-
dence injecting preperation expertise and explain
additional acidifier need. This was primarily in relation
to the demands of preparing injections with poor quality
heroin or crack cocaine (‘white’). As Troy says:
When you’re doing snowballs [heroin and crack] you
have to have a bit more citric … like the white won’t
dissolve if you don’t have enough citric in it.
Mason also educates on the need for acidifier depend-
ant on drug type and heroin form:
Right, see when you use crack you need to put citric
in to dissolve it, see when you use coke it just
dissolves … the brown heroin is the same as the
white heroin … It’s just cheaper to not to [process]
it, so they just leave it brown, it’s cheaper to make
and all you do is put citric in it.
Here, heroin refinement and purity are closely tied to
the need for acidifier. These accounts often link to early
injecting experiences. Marc recalls when he started
injecting in the 1970’s: “It was pretty strong stuff. I mean
I didn’t use any substance to dissolve it. We just heated
it up on the spoon, with water, you know”. Although he
later refers to this heroin as ‘brown’ indicating Afghani
heroin (requiring acidification), other narratives indicate
the presence of different heroin forms (such as salt form,
non-smokable, heroin) in the ‘early days’. Ryan explains
why he uses more acidifier now: “The gear [heroin] was
better, like when I started using gear it wasn’t smoked,
you know what I mean, it wouldn’t burn on the foil,
yeah proper, proper gear.”
Expert accounts convey conviction and a strong ra-
tionale for additional acidifier use. For many, however,
this rationale was undercut by a tension – between
knowledge in theory and preference in practice. Mason
speaks of the need for more acidifier when preparing
heroin of poor quality, while simultaneously reflecting
that, in effect, all this acted to do was break down less
soluble cutting agents. His account deflects the problem-
atics of this practice by framing it in terms of what ‘most
people’ do, while briefly acknowledging that it is also
part of his routine:
Most people think a sachet is for a bag … but see
what the problem is, see all the crap that goes into
smack, me and a lot of people, see when you cook up
you’re trying to get that to dissolve because you don’t
know what it is, yeah. You put more fucking citric in
it and in reality, it’s not going to dissolve, but it could
be anything, do you know what I mean, so that’s how
people use loads of citric.
Dev also acknowledges that excess acidifier is used to
break down cutting agents, moving from the third to
first person to express this as a shared practice: “Yeah,
you’re a user know what I mean, it’s going to be in your
head, because you don’t want to waste no little bit, know
what I mean, I want every little bit.” Logan would use up
to two sachets of citric to prepare an injection, saying:
“Just see how it breaks down, put like a sachet in, if it
doesn’t break down you add more”. He was aware that
this was ‘probably’ too much: “but when you see it
[‘crap’] in the spoon, you just think, bugger it”. Some
participants, such as Matt, spoke with equal certainty of
the need to use more acidifier for poor quality heroin,
but without necessarily the awareness that this is
problematic:
Table 1 Injecting and treatment history: PWID London 2017–2019 (Continued)
Demographics and injecting history N = 455
Heroin and crack combined 61 (35.7)
Stimulants (amphetamine, methamphetamines, speed) 4 (2.3)
Crack (only) 2 (1.2)
Methadone 1 (0.6)
Steroids or other performance enhancing drugs 1 (0.6)
Treatment history
Ever been on opiate substitution therapy (OST)
Yes, currently 360 (79.1)
Yes, not now but in the past 62 (13.6)
No 33 (7.3)
Duration on opiate substitution therapy, if receiving OST currently n = 360
Duration on OST (years), median (95% CI) 10 (7.10)
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Table 2 Distribution of usual injection preparation and practices: PWID London 2017–2019
Injecting preparation, patterns and health outcomes N = 455
n (%)
Main acid used to dissolve drugs for injecting in the last 12 months n = 284
Citric acid 237 (83.5)
Vitamin C 27 (9.5)
Lemon juice 4 (1.4)
Kettle descaler 1 (0.4)
No acid 15 (5.2)
Typical (usual) quantity of citric acid or vitamin C used to prepare
a £10 bag of heroin
n = 418
More than a sachet 5 (1.2)
A whole sachet 122 (29.2)
¾ of a sachet 23 (5.5)
½ a sachet 136 (32.5)
¼ of a sachet 41 (9.8)
A pinch 91 (21.8)
Body site injected over lifetime
Hands 333 (73.2)
Arms 439 (96.5)
Neck 169 (37.1)
Groin 189 (41.5)
Legs 275 (60.4)
Feet 251 (55.2)
Other 63 (13.9)
Frequency of injecting in a typical week
Once a week 57 (12.5)
2–4 times a week 50 (11.0)
4–6 times a week 31 (6.8)
Once a day 44 (9.7)
2–3 times a day 164 (36.0)
4 or more times a day 109 (24.0)
Number of times usually insert the needle before successful
vein injection
Once (I always get it the first time) 202 (44.4)
Twice 82 (18.0)
3–4 times 58 (12.8)
4 or more times 108 (23.7)
I do not inject into a vein 5 (1.1)
SSTI history and hospitalisation
No 159 (35.0)
Yes, but not hospitalised 159 (35.0)
Yes, and hospitalised 137 (30.0)
Ever diagnosed with DVT N = 455
No 350 (76.9)
Yes 105 (23.1)
Ever diagnosed with blood poisoning
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Sometimes you [need more] depending on the
gear. Because I know how much citric I’ve used,
and I’m used to how much I put on, and
sometimes like you cook it up and you can tell
that you need to add a little bit more to cook it
up further and just depends what they cut the
gear with I guess.
Dean, who initially draws on his expertise to ex-
plain how risk is identified (foil running red) and
mitigated against (avoiding citric), further illustrates
the tension between expert knowledge and
routinised practice:
My brother’s a smoker, so I can see on his foil that it’s
running red, so I know it’s got shit in it already and like
if I ain’t got Vit C and I have to use lemon, all lemon
will cook up is the gear, it won’t wash all the other shit
they put with it. So you can see it all in the bottom of
the cup, like all the crap. Citric generally washes
everything up, even the shit, so you don’t really know.
When you use lemon juice or vinegar it just washes the
gear up and leaves all the shit in the bottom of the cup.
While the above account indicates care taken to avoid
injecting impurities, Dean’s preference in practice under-
mines this impression:
Table 2 Distribution of usual injection preparation and practices: PWID London 2017–2019 (Continued)
Injecting preparation, patterns and health outcomes N = 455
No 372 (81.8)
Yes 83 (18.2)
Ever diagnosed with endocarditis
No 433 (95.2)
Yes 22 (4.8)
Current albumin-creatinine ratio (past 12 months) N = 316
Normal 254 (80.4)
Abnormal/high abnormal 62 (19.6)
Table 3 Unadjusted and adjusted odds ratios (OR) with 95% CI for the risk of groin injecting, micro/macroalbuminuria, diagnoses of
DVT and septicaemia among high acidifier use
Low acidifiera (%) High acidifierb (%) OR bivariate (95% CI) P value AOR multivariatec (95% CI) P value
Ever injected in groin
No 168 (63%) 70 (47%) 1 – 1 –
Yes 100 (37%) 80 (53%) 1.92 (1.28, 2.88) 0.002* 1.95 (1.29, 2.95) 0.002*
Ever diagnosed with DVT
No 213 (79%) 102 (68%) 1 – 1 –
Yes 55 (21%) 48 (32%) 1.82 (1.16, 2.87) 0.010* 1.87 (1.18, 2.97) 0.008*
Current Micro/macroalbuminuriad
No 152 (64%) 85 (36%) 1 – 1 –
Yes 27 (49%) 28 (51%) 1.85 (1.03, 3.35) 0.041* 1.85 (1.02, 3.35) 0.042*
Ever diagnosed Septicaemia
No 225 (84%) 115 (77%) 1 – 1 –
Yes 43 (16%) 35 (23%) 1.59 (0.97, 2.63) 0.068 1.60 (0.96, 2.67) 0.070
Ever diagnosed Endocarditis
No 258 (96%) 139 (93%) 1 – 1 –
Yes 10 (4%) 11 (7%) 2.04 (0.85, 4.93) 0.113 2.27 (0.91, 5.66) 0.077
OR odds ratio, AOR adjusted odds ratio, DVT deep vein thrombosis
aTypically uses half or less of acid in drug preparation
bTypically uses more than half of acid in drug preparation
cAdjusted for age, gender and injecting frequency per week
d292/316 responses for acid use among those who provided urine samples
*Significant at p < 0.05
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I prefer citric, to be honest, but if I was in my logical
mind I’d use Vit C rather, because that doesn’t wash
all the impurities up, that just washes all the actual
gear and then all the shit that’s in it, it leaves in the
bottom of the cup as well with Vit C.
Dean speaks in some detail of how citric, vitamin C,
lemon and vinegar interact with heroin of varying purity.
Six interview participants mention using lemon juice for
injection preparation. Dean is the only one who con-
tinues to use household acids on a frequent basis:
[I use lemon and vinegar] loads of times, maybe for
every ten times I inject probably two or three times,
yeah, because I use so much citric for one bag, like
the whole sachet, I run out of it constantly.
His use of lemon juice also appears excessive: “it stings
quite a lot because generally I don’t put water in with it,
I just use neat lemon juice … I’m destroying my, now
you know why my veins are so knackered.” While attrib-
uting venous damage to lemon juice use he was unaware
of its potential to cause candida infection (“No, I haven’t
heard about that. How does it affect your eyes?”). Other
participants were aware of the risks, with some using
other household materials to mitigate damage where no
alternative to lemon was possible:
[In prison] if you’re going to use lemon juice … get
a teabag and pour it through a teabag so you’re
making it as pure as you can, getting all the little
bits out. … See all the little bits of pith and that,
when you cook up and draw it up, that’s what
going to make you go blind and shit like that, and
it’s quite scary. (Mason)
Constraint and convention: ‘one for one’
While ‘experts’ generally took ownership of acidifier
overuse, drawing on the logics of experiential knowledge
and preference, a distinct group of participants attrib-
uted their injecting practice to external factors. Here, ex-
cess use of acidifier was accounted for in relation to
structural or information constraints or as following
convention set by sachet size. For those referencing con-
straint, excess use was recognised as such and, where
possible, injecting practice changed in response. Those
referencing convention seldom illustrated movement in
practice, using “1 for 1” [one sachet for one bag] was
something they had ‘always done’ and was rarely subject
to reflection. The following exchange is indicative:
M.H: How much citric would you put in for say a £10
bag?
Tim: Well they come in little sachets, so one of them.
A whole sachet?
Yeah.
Have you always used a whole sachet?
Yeah …
Do you use a whole sachet just because that’s how
much there is in the sachet or because that’s how
much you feel you need to get it to work properly, to
get it to dissolve?
No, that’s how much is in the thing, just rip it open,
yeah.
While ‘experts’ might add an acidifier gradually, in-
creasing the amount until the mixture was clear (even
with awareness that this was not needed), those
responding to convention would generally use a whole
sachet at once; the act of ‘opening it up and tipping
it in’ requiring little thought or modification. Isaac
explains: “I put it all in at once because I always been
like that, I put gear in then I put the citric in, it just
does it automatically, does that make sense?” For
these participants, expertise is located with injection
equipment manufacturers and providers—sachet size
is an assumed guide to good practice. As Mason says:
“most people think a sachet’s for a bag.”
Participants referencing structural or information
constraints might also speak of using ‘1 for 1’ but in
the past tense—in relation to past uninformed or con-
strained practice. This was often with some bitterness
and regret:
I used to use the full packet, I used to think you had
to use the full bleedin’ packet, I mean I didn’t know,
no one likely to say oh hang on, you didn’t use, you
don’t need to use all that. (Alex)
Ray similarly speaks of learning to inject in relative
isolation from peer-based knowledge or expert guidance:
We didn’t take care or know how to inject properly,
so our veins were fucked quick, really quick. [MH:
why were they fucked?] Oh, not rotating, probably
using too much citric and using the wrong sized
needles.
Both participants explicitly relate their early use of ‘1
for 1’ to venous damage, with practice modified over
time in response:
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When I started getting like citric burns and that, I
used to put a little bit less in and see what it would
do, yeah, because you don’t need to use all that much
do you. (Alex)
Ray drew on manufacturing and access constraints to
account for his early practice, with an associated plea for
transparency of process, clear information and availabil-
ity of alternatives:
Oh I was whacking a whole bag in, yeah, because
that’s another thing as well I mean I’m sure the
machine that puts it into the sachets, it can either,
that’s the least amount they can set it to, or if they
put it any less the amount of moisture that seeps
into the packet it just, you know, it’ll ruin it, but I
don’t know, it should be more clear on the packet,
or they should … In London, when you go to the
chemist they only give you citric, they won’t give
you vit C.
For others, constraints operated both at the level of
equipment provided and power dynamics inherent to
their injection practice. Kirsty did not know how to pre-
pare heroin and crack for injection and relied on her
partner to both prepare and administer each injection:
MH: Do you see your man cook up? Do you know
how much citric he puts in and stuff?
Kirsty: A whole bag. … it really burns. Really burns
He might be using a bit too much citric.
Yeah. That’s what I told him. “No it’s not, no it’s not”.
[He gave me] a mouthful of abuse ... And he knows I
need it, so what can I say? I’ve just got to accept it
haven’t I?
Whether Kirsty’s partner would be open to modify-
ing his practice in relation to ‘expert guidance’ (for
example, information printed on each sachet packet)
is unknown. However, the witnessed dynamics of his
relationship with Kirsty made it clear that her re-
quests would be more likely to entrench rather than
shift potentially harmful drug preparation practice,
particularly if he took on an ‘expert’ role within the
relationship.
Given the constraints and convention attributed to acid
sachet size, all participants were asked which and how
much acidifier they used before sachet availability. Most
spoke of buying citric or vitamin C in bulk from pharma-
cies or grocery stores and using only ‘a pinch’ during drug
preparation. As Marie relates: “I bought it from the chemist,
big tub of that, only cost about £1 or £2 and it lasts you for-
ever … you put a tiny sprinkling in”. Katy expressed a con-
tinued preference for pharmacy sourced vitamin C powder,
and like others, the quantity sourced appeared to positively
impact amount used: “You just use little bit, little bit, be-
cause it’s a big tub … just little pinches”. When asked if this
was likely to be less than from a sachet, she replied “Yeah,
yeah, yeah, I think you do, I think you do [use less]”. Prefer-
ence was also subject to constraint, with some no longer
able to source vitamin C powder: “they used to sell them in
little orange tubs in Boots but now they’re just tablets and I
don’t know, because they’re orange tasting tablets I don’t
really want to.” (Matt).
Attributing pain: normalisation and modification of practice
Painful injections, with a burning sensation experienced
on administration, were common to participant accounts.
For some, painful injections resulted in a modification to
practice—with less or a different acidifier used. For others,
this pain appeared to be normalised—an accepted part of
the injection process, with little or no injection prepar-
ation modification. All attributed painful injections to the
use of acidifier—primarily citric acid. Jade provides a vis-
ceral rendition of ‘citric burn’:
Citric, it burns your skin and you can feel it through
your veins, and it’s a horrible feeling … When it burns
it brings up all the veins, if you miss a hit oh my God,
the citric tears you down, I’m talking about it can take
you to the point where you’re whole hand turns red
you know, all your hand, the middle of your palm is
red because of the citric.
Many articulated a causal pathway from acidifier use
to painful injections and venous damage: “you have the
hit and then that vein’s destroyed because of the citric”
(Mason). Some modified their practice in response:
I put as little [citric] as possible. I actually put less
than other people, “oh put the whole bag in” and no, I
put like a pinch in and I was aware of what it was and
I thought this stuff is painful so I’m, like, little as
possible … I really do think personally that it’s one
of the major causes of losing your veins. It’s not
the drug, it’s the Vit C or the citric. (Ian)
While Ian speaks of vitamin C and citric in the same
context, most participants made a clear distinction. For
some, citric was preferred due to its perceived ‘strength’
while those concerned with pain and venous damage
tended to favour vitamin C:
Vit C is wicked because when I was on like, finger
veins and shit, if I used citric that’s it, one use, that
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vein is gone. If I use vit C I could get a week out of
one. (Ray)
Preference for citric tended to align with a normalisa-
tion and acceptance of painful injections, with little asso-
ciated modification to drug preparation practice. Dean
notes, “I’ve had loads of citric burns, yeah, it stings like
fuck…. [but I] still do it, still use the whole sachet now”.
Ian normalised injection site skin reactions and pain, at-
tributing them to “the citric … normally you get that
when you get a vein, it’s just part and parcel, isn’t it?”
Here, modification was more likely to take place during
drug administration than preparation—with potentially
risky consequences:
What happens is like I’ll suddenly get this citric burn
and then I’m forced to go looking elsewhere and then
I have to go deeper and I have to use the 2ml barrel
pins to get deeper. (Matt)
This movement from use of peripheral to deep veins,
such as the jugular or femoral, is associated with increased
risk of complications and SSTI [28]. Tim comments that
now he uses deeper, bigger veins he no longer feels the
citric burn as he did in his peripheral veins. Emma’s modi-
fied practice is also associated with additional risk: “I put
too much citric in and it started burning me you know, so
I had to take it out, it was too much, I … skin popped it.”
Purposeful arterial injecting was also described, with pain
negotiated through administration practice:
You’ve got the little digits [on the syringe], if you put
a ten unit in or more the burning will be too much to
take. What you do is you put a little, like, two bit, one
of the little lines in, you wait, it’ll burn, it’ll die down,
with another bit it’ll burn, it’ll die down and you’re
like that and that’s how you do it in your artery.
(Logan)
Participants less likely to reduce their acidifier use (‘ex-
perts’ and those following convention) were more likely
to normalise pain. Those who spoke of a modified prac-
tice acted to avoid pain, and critiqued perceived struc-
tural constraints to doing so. While above, Matt
attributes an almost malicious intent to the manufac-
turers of acids for injection: “it’s like they want you to
burn yourself or something”, Jade states that current
provision lacks insight into the needs of PWID:
I think that they should find other things that’s not
going to damage people’s skin and all that. The citric
burns your skin, I don’t think it’s fair … it’s bad
enough people have a habit, but at least help them.
I mean it is great, I’m grateful that they do, they
gave us needles at the time, but when these people
that pack these bags, they’re not people that use. If
they was a user they would have more of an insight of
what a person would be happy with… citric would be
out of bounds… instead of citric, vitamin C is the best.
Matt references the constraints of sachet design while
providing another narrative of pain, venous damage and
loss:
Like a couple of times I’ve opened the packets and
they’ve been quite full and they’ve just exploded
over the spoon and just gone everywhere onto it
and it ended up being like more than what I would
normally put on. And yeah, my skin sort of just
bubbles up and my veins just disappear immediately if
I use too much citric… it’s like a burn, literally like a
burn… it travels from where the veins split off … it will
go quite a way, yeah, good foot and a half I’d say.
Discussion
Injecting practice is shaped by a complex interplay of so-
cial and environmental factors [29] and is not uniformly
productive of risk. Perceptions of and importance
afforded ‘risk’ among PWID are also variable, informed
by access to resources, hierarchies of priority, temporal
orientation, environmental constraints, agency to effect
change, and social relations and norms [30]. Qualitative
accounts highlight the situated rationalities at play in in-
jection preparation practice, with attributions of expert-
ise mapping onto preparation practice and its variation
or stability over time.
In combination with quantitative results, we posit that
excessive acidifier use in injection preparation is com-
mon among PWID in the UK and can play a causative
role in venous damage and associated sequelae. The pro-
portion of participants reporting excessive acidifier use
align across datasets, with 36% of the survey and 37% of
the interview participants reporting typical use of more
than half a sachet of acid in injection preparation with
nearly a third (30% and 31%, respectively) using a whole
sachet or more.
A limitation of the quantitative data is that variation in
acidifier use over time is not ascertainable; the question
pertaining to acidifier quantity lacks time period specifi-
city. Given we employ the present tense to ask partici-
pants how much acidifier they typically would use when
preparing a £10 bag of heroin, it is likely that answers
reflect recent practice. Qualitative data provide a more
nuanced picture of use over time and supports interpret-
ation of quantitative data as pertaining to current use.
Interview accounts illustrate 37% currently or recently
using excessive acidifier and that for the majority, the
Harris et al. Harm Reduction Journal           (2019) 16:60 Page 11 of 15
amount used remained relatively stable throughout their
drug use trajectory. This was particularly the case for par-
ticipants who located their acidifier use within an expert-
based practice (whereby the quantity used is determined
by visual cue of injection clarity) and for those who lo-
cated their practice in relation to external expertise (with
quantity used determined by packet size). Some illustrated
change over time, with acidifier use generally decreasing
in relation to information gained or pain on injection
practice. For these participants, constraint rather than ex-
pertise informed early acidifier use, with critical reflection
provided on both the limitations of manufacturing guide-
lines and information provision. Data triangulation indi-
cates that quantitative results likely pertain to current
practice, with typical amounts of acidifier used across the
injecting career higher for a sub-sample. This has implica-
tions for analyses pertaining to health harms, given vari-
able duration of progression from venous damage to SSTI
and associated complications.
Quantitative analyses show no significant associations
between quantity of acidifier use and SSTI. Qualitative
accounts, however, paint a vivid picture of ‘citric burn’
and proximal venous loss. Pain on injection was com-
mon, and unanimously attributed to the use of acidi-
fier—particularly citric acid. For some, this led to the
use of deeper veins for injection, including the femoral
vein. Qualitative analyses helped inform questions asked
of statistical analysis, including in relation to indications
of venous damage such as femoral injecting. We found
statistically significant associations between excessive
acidifier use (> ½ sachet), femoral injecting and DVT.
This, in combination with reference to the literature and
qualitative analyses, supports our hypothesis of a causal
pathway between acidifier overuse and venous damage.
For example, Harris and Rhodes [13] detail the suffering
and frustration experienced by PWID who have diffi-
culty accessing damaged peripheral veins. Half of their
qualitative London sample transitioned to using the fem-
oral vein, even though it was positioned as ‘a last resort’
by many. Our survey sample also comprises a high pro-
portion (42%) of PWID reporting femoral vein injecting,
indicating peripheral venous damage.
Our data support earlier studies demonstrating that,
for many PWID, the end point of injection preparation
is determined by a clear solution, when all drug material
appears from visual inspection to be dissolved [2, 31].
This is problematic given components in the injection
such as adulterants, excess bicarbonate in crack cocaine,
and plant-based materials in heroin may not necessarily
dissolve at the same pH as the drugs themselves. The ex-
cess acid required to dissolve these materials increases
injection solution acidity but not psychoactive drug con-
tent. ‘Expert’ participants demonstrated awareness of
this but were reluctant to take the leap of faith required
to use less acid in a context of uncertain drug quality.
Here, rather than educational interventions, the
optimum point of intervention becomes the drug itself—
or the acid used to prepare it. Participants who externa-
lised expertise rarely problematized their acidifier use,
with trust placed in the convention of sachet size as a
guide to good practice. Given variation in practice, with
‘experts’ adding acidifier step-wise dependent on visual
cue of drug clarity and those adhering to convention ha-
bitually using a whole packet at once, intervention at the
level of equipment manufacture is also desirable. For
participants referencing constraint, some who initially
may have adhered to convention, clear information
provision was required. Below, we consider each of these
intervention points: the drug, the acid, equipment manu-
facture and information provision, exploring constraints
and enablers to each in the UK policy environment.
The drug
While there are many variables impacting venous dam-
age, femoral injecting and SSTI risk, it is crucial to
understand how heroin source, form, chemistry and
quality informs local drug preparation and administra-
tion practice in order to intervene at the level of health
harm. Geographical variation in heroin source and form
has implications for SSTI prevalence. In the US, for ex-
ample, cities with a dominance of Mexican-sourced
“Black Tar” heroin (BTH) report 40% higher rates of
SSTI compared with cities supplied by Colombian
sourced powder heroin [16, 32]. London participants
using Afghanistan sourced brown base heroin report
painful injections and vein damage, unlike Philadelphia
participants using salt form heroin [8]. In a context of
prohibition, heroin quality is variable and difficult to de-
termine. This also has implications for injection prepar-
ation practice. Our data illustrate that even with
awareness of the ‘ideal amount’ of acid to use, many
PWID will use more to dissolve poorly soluble cutting
agents or adulterants such as paracetamol and quinine.
Structural problems require structural solutions. Dia-
morphine hydrochloride, pharmaceutical grade heroin, is
readily soluble in water with a resultant pH of 4, which
is less likely to cause vein damage. Department for
Health registered doctors can legally prescribe pharma-
cetical grade heroin in the UK, but this is not supported
by policy in practice. As beginning to be recognised with
‘party drugs’, such as MDMA, adulterants can cause sig-
nificant health harms. Pill testing has gained traction
and not before time [33]. In the absence of quality con-
trol, testing for the diamorphine content of heroin and
confirmation of its presence in the base form would
allow calculation of the amount of acid needed in prep-
aration [2]. The logistics, feasibility and acceptability of
this approach are, however, unclear.
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The acid
Given current legislative constraints to the provision of
safer drugs for injection or testing to determine quality,
modifications to acidifier provision require consider-
ation. NSP throughout the UK primarily provide citric
acid sachets, and vitamin C is less readily available. The
question of which acid represents a lesser risk of harm
has been subject to laboratory experiment [9]. Labora-
tory testing of injections prepared using methods repli-
cated from PWID found citric acid produced injections
with a lower pH (which will be more locally irritating)
and vitamin C produces injections with a higher osmo-
lality (could cause vein damage if given rapidly) [9]. As
larger quantities of vitamin C are needed to convert base
drug to a soluble form, there is a greater margin of error;
excess vitamin C use will not be as irritating as excess
citric acid. High amounts of vitamin C in injection prep-
aration can cause precipitation (a solid clouding in the
injection solution); a potential deterrent for excess use.
There is a case to be made, therefore, for phasing out
citric acid distribution in favour of vitamin C. In re-
sponse to presentation of our data [34], the pan-Dorset
Harm Reduction group, in consultation with service
users, has removed citric acid from Dorset NSPs in
favour of vitamin C [35].
Ciccarone and Harris [8] found that the pH of her-
oin solution prepared with vitamin C (3.4) was still
too acidic for healthy veins. They propose develop-
ment and supply of another mild, yet effective organic
acid. The provision of sterile buffered solutions (acidic
solutions in which the extent of the pH drop is con-
trolled by the addition of harmless chemicals) could
be an alternative to vials of water for injection plus
acid sachet. Such buffering is routinely used in the
manufacture of pharmaceutical injections, and a range
of chemicals are approved for use by medicines licenc-
ing agencies. The challenge lies in regulation, with
such products likely to be classified as medicinal prod-
ucts. Manufacturers are then subject to onerous medi-
cine regulation, testing and licencing. For individual
PWID, a pinch of sodium bicarbonate (baking soda)
could be added at the end-stage of drug preparation to
buffer the solution. This practice is incorporated into
injection preparation by some PWID in New Zealand,
where citric and other acidifiers are used in the prep-
aration of heroin from morphine sulphate tablets,
‘homebake’ and opium [36].
Equipment manufacture and provision
Modifications to the manufacture and supply of acids cur-
rently available for injection may be the most feasible op-
tion in the short term. Some participants expressed a
preference for vitamin C but found it difficult to access.
‘Choice’ of acidifier is constrained by availability – injecting
supply bags provided through pharmacy NSP often only
contain citric acid. Providing sachets of citric and vitamin
C in each pack or promoting choice in other ways could
support uptake of vitamin C. Sachet size will, however,
still pose a constraint to good practice. This is a potent
signifier of appropriate quantity, and use of one sachet for
one bag of heroin (‘1 for 1’) was common among our par-
ticipants and in the few other studies where details of
acidifier use are documented [3, 9, 10]. As a ‘single use’
item, one sachet is generally provided for each needle and
syringe. Information to use less than a whole sachet is
present on a small proportion of sachets from one manu-
facturer only. Options for acting on the constraint of sa-
chet size include: diluting acid strength with a harmless
bulking agent; revisiting the use of pharmaceutical grade
manufacture to provide smaller ‘food-grade’ sachets; add-
ing a scoop in or alongside sachets; returning to bulk
provision. The content of vitamin C sachets could be re-
duced from the current 300mg weight to a lesser weight
that theoretically provides enough acid to dissolve a ‘typ-
ical’ street deal of heroin, such as 150mg. All of these op-
tions contain their own constraints, none are ideal.
The dilution of citric acid with a harmless soluble powder
approved for injection manufacture before the 100mg fill
weight is measured could offer some protection when a ‘1
for 1’ approach is taken, especially for PWID who adopt
this as routine practice. It would not obviate against the use
of additional acidifier to dissolve cutting agent residue.
Acidifier sachets as currently supplied are not considered
medicinal products by the regulator (MHRA). It is less clear
whether this would be the case if dilution of the acid was
undertaken prior to fill. Reducing the sachet size of citric
acid is not possible if adhering to industry Good Manufac-
turing Practice sachet filling standards (where 100mg is the
lower limit) but could be possible if supplied to ‘food grade’
standard which is not subject to weight standardisation
constraints. Single use sachets of acidifier were developed
to support optimal injecting practice, in which injections
are prepared for and by the individual with no equipment
shared. The contents are sterilised to reassure providers
that products supplied to PWID support pharmaceutical
injection preparation much as can realistically be achieved.
Some participants, however, recalled using smaller amounts
of acid for preparation when sourced from larger pots. The
presence of a quantity in the pot obviously in excess of re-
quirements paradoxically seems to have promoted stepwise
addition of smaller amounts. Removal of sterilisation con-
straints and/or return to bulk provision could meet resist-
ance due to concerns about risk of bacterial infection from
the acid itself. Given these constraints, and in response to
our findings [34], one UK manufactor has collaborated with
us to change the messages on their citric and vitamin C sa-
chets to stress that “a whole sachet is far too much for most
injections” (see Fig. 1).
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Reinvigorating harm reduction messaging
‘Expert’ accounts drew on practical and theoretical
knowledge to both justify and undermine the excessive
use of acidifier—primarily in relation to the preparation
of snowballs and poor quality heroin. The distinction be-
tween preference in practice and ‘logical’ knowledge is
problematised in a context of uncertainty. When “you
try to dissolve it because you don’t know what it is”
(Mason), both logic and preference are undermined. To
leave residue in the spoon requires trust—a ‘leap of
faith’—that injection strength will not be compromised.
Familiarity with and trust in the science of heroin pre-
paration can aid such a leap. A harm reduction video,
demonstrating the chemistry of street heroin prepa-
ration, provides an innovative response to such need
[37]. Here, a heroin injection is prepared in a laboratory
setting, with small amounts of citric acid added in a
stepwise process and the chemistry involved explained.
Available in DVD and through online social media, the
video targets PWID and drug service practitioners, but
participant accounts suggest limited awareness with no
evidence of uptake by drug treatment services.
There is an evident need for clear information to sup-
port heroin preparation practice, particularly given PWID
uncertainty about acidifier use reported in multiple UK
studies [8, 11]. Retrenchment of social and public health
services in the UK coupled with a ‘recovery’-focused drug
policy agenda has decimated drug treatment services and
the capacity and confidence of staff to provide fundamen-
tal safe injecting advice. The provision of non-stigmatising
services attuned to the priorities of PWID, such as vein
care and injection preparation, can help to reengage mar-
ginalised PWID and prevent health harms [13]. Safe
injecting sessions, including information on drug prepar-
ation chemistry, should be integral to service provision in-
cluding pharmacy-based needle and syringe provision.
Clear and consistent messaging is required on all acid sa-
chets, with pamphlets detailing optimal injecting practice
and preparation in all equipment packs. While important,
these initiatives must not act in isolation from structural
change. An individualisation of responsibility, common to
health promotion messaging, can be counterproductive in
the context of constraint—acting to further stigmatise and
marginalise rather than empower. There is little use, for
example, informing of the need to use sterile equipment
or to favour vitamin C if equipment access is constrained.
Conclusion
Venous damage and chronic injecting-related problems
are common to the experience of PWID. To reduce
injecting-related injury and associated consequences, we
contend that it is crucial to understand the interplay of
environmental and practice-based risks underpinning
venous damage among PWID. The use of acid in injec-
tion preparation can precipitate vein damage and is
amenable to structural and practice-based change. In the
absence of policy reform to enable provision of safer
drugs for injection, there is an urgent need to revisit
injecting equipment design and distribution in order to
alleviate health harms and distress among the most mar-
ginalised. This could include modification to the form
and/or packaging of acids currently available. This paper
evidences research impact on practice, with modifica-
tions made to acidifer supply (Dorset) and sachet design
(Exchange Supplies) in response to findings dissemin-
ation. These are welcome first steps, incorporating edu-
cational intervention with structural change.
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